| ACEM PRIMARY 1/2008 Pharmacology VIVA Morning Day 1 | Candidate Number | AGREED MARK |
|---|------------------|-------------|
|---|------------------|-------------|

| TOPIC | QUESTION | ESSENTIAL KNOWLEDGE | NOTES |
|----------------------|---|--|-------|
| Second Messengers | In reference to drug action what is a second messenger? | A chemical eg Ca++ or cAMP that converts receptor binding to end effect through the production of an active intracellular element. | |
| | What steps are involved in the action of a drug via a second messenger ? (Prompt - Illustrate this with an example) | Extracellular ligand specifically detected by a cell-surface receptor. Receptor triggers the activation of a G protein located on the cytoplasmic face of the plasma membrane. Activated G protein changes the activity of an effector element (usually enzyme or ion channel) This element changes the concentration of the intracellular second messenger. Example cAMP - Gs stimulates adenylyl cyclase which converts intracellular ATP to cAMP which stimulates cAMP-dependent protein kinases. Ca, Phosphoinositides cGMP (Pass –understanding of the concept that there may be a secondary process producing drug effect and able to name at least 1 second messenger) | |

| Angiotensin 2 | Describe the pharmacodynamics of | ACE inhibitors – bind ACE reversibly preventing | |
|---------------|---|---|---|
| Blockers | therapeutic drugs that modulate the effect | conversion of AI to AII. | |
| DIOCKEIS | 1 0 | | |
| | of angiotensin | Inhibitory action on the renin-angiotensin system | |
| | (Prompt to ACE & receptor blockers) | Stimulating action on the kallikrein-kinin system | |
| | What are the advantages of Angiotensin | Angiotensin II inhibitors – competitive antagonists | |
| | 2 receptor antagonists over ACE | at A II receptor. | |
| | inhibitors ? | As AII inhibitors do not result in production of | |
| | (Specifically with respect to side effects) | bradykinins, there is a decreased incidence of | |
| | | cough and angioedema. | |
| | | Potentially greater effect as enzymes other than | |
| | | ACE can generate AII | |
| | | (Pass – able to describe actions and basic effects of | |
| | | ACE inhibitors and understanding that AII | |
| | | receptor antagonists and ACE inhibitors have | |
| | | different mechanisms.) | |
| LMWH | What are the pharmacodynamic | Enoxaparin predominantly binds and inhibits | |
| | differences between low molecular | factor Xa function, UFH binds to AT that inhibits | |
| | weight and unfractionated heparin? | factors II, IX, X | |
| | | | |
| | What are the advantages of low | Single daily or divided subcutaneous doses – | |
| | molecular weight heparin over | facilitates patient mobility and OPD management. | |
| | unfractionated heparin? | Routine monitoring not required (not mentioned in | |
| | | book) Reduced bleeding risk. Lower incidence of | |
| | | HITP. Improved efficacy over unfractionated | |
| | | heparin in ACS. | |
| | | Increased bioavailability | |
| | | , i i i i i i i i i i i i i i i i i i i | |
| | | (Pass – dosage differences and bleeding risk as | |
| | | well as factors II and IX less inhibited by LMWH | |
| | | (or at least that APTT is not accurate measurement | |
| | | of anticoagulation) | |
| | | | |
| | | | I |

| Atropine | What is the mechanism of action of atropine ? | Antimuscarinic at cholinergic receptors | |
|------------|--|---|--|
| | What are the toxic effects of atropine? (Prompt - due to excessive use or abuse) | Tachycardia, flushing, dry skin mucous, mydriasis membranes, ileus, urinary retention, acute angle glaucoma, central anticholinergic syndrome (delirium with visual hallucinations) | |
| | What are the therapeutic uses for atropine ? | Symptomatic bradycardias, especially when vagally mediated. OGP poisoning/ Inocybe Mushroom poisoning, drying of secretions. Adjunct to reversal of non depolarising muscle relaxants and suxamethonium administration in young infants. Antispasmodic, mydriatic. | |
| | | (Pass – antimuscarinic, at least 2 indications and 3 adverse effects involving 3 different body systems) | |
| Octreotide | Explain the rationale for the use of octreotide in upper gastrointestinal bleeding | Octreotide reduces splanchnic blood flow, (? By glucagon release inhibition) therefore reduces portal venous pressure. This reduces blood loss from bleeding oesophageal varices and in some cases of severe duodenal ulcer related bleeding. | |
| | What are the pharmacokinetic differences between octreotide and somatostatin? | Octreotide is a somatostatin analogue that has a longer half life than somatostatin (1.5hrs vs 3 min) so can be given as an IV infusion or subcutaneously. | |
| | (Supp Question – What other agents may be useful in the prevention and treatment of upper GI bleeding) | (Pass – reduces splanchnic blood flow) | |

ACEM PRIMARY 1/2008 Pharmacology VIVA Afternoon Day 1 Candidate Number...... AGREED MARK......

| TOPIC | QUESTION | ESSENTIAL KNOWLEDGE | NOTES |
|---|---|---|-------|
| Competitive vs Irreversible Antagonists | What is an antagonist ? Explain the difference between a competitive and irreversible antagonist (Illustrate this with an example) | Receptor antagonists bind to receptors but do not activate them. The primary action of antagonists is to prevent agonists from activating receptors In the presence of a fixed concentration of agonist, increasing concentrations of a reversible competitive antagonist progressively inhibit the agonist response; high antagonist concentrations prevent response completely. eg Propranolol and Noradrenaline Irreversible antagonists bind to the receptor either by forming a covalent bond with the receptor or by binding so tightly that the receptor is unavailable for binding of the agonist eg Phenoxybenzamine vs adrenaline | |
| | | | |
| | | Changes in agonist concentration-effect curves produced by a competitive antagonist (Panel A) or by an irreversible antagonist (Panel B). In the presence of a competitive antagonist, higher concentrations of agonist are required to produce a given effect; thus the agonist concentration (C') required for a given effect in the presence of concentrations can overcome inhibition by a competitive antagonist. This is not the case with an irreversible (or noncompetitive) antagonist, which reduces the maximal effect the agonist can achieve, although it may not change its EC_{50} . Pass Be able to distinguish between competitive and irreversible antagonist | |
| Loop Diuretics | How does frusemide exert its action ? | Selective inhibition of NaCl reabsorption in the thick ascending loop of Henle | |
| Ĩ | What are the adverse effects of frusemide? (Are any other organ systems effected ?) | Hypokalemic Metabolic Alkalosis Ototoxicity Hyperuricemia Hypomagnesemia . Allergy Skin rash Eosinophilia Interstitial nephritis Hyponatremia | |
| | | Pass – Na & loop of Henle, 4 adverse effects incl hypokalaemia & one non electrolyte | |
| Methylxanthine | What are the organ system effects of theophylline ? (Prompt both therapeutic and toxic) | CNS: Mild cortical arousal with increased alertness and deferral of fatigue. Bronchodilation. Nervousness and tremor. Overdose causes medullary stimulation, convulsions and death. | |
| | | CVS: Positive chronotropic and inotropic effects by inhibiting presynaptic adenosine receptors in sympathetic nerves and increasing catecholamine release at nerve endings. Produces tachycardia, increased cardiac output and BP. May cause arrhythmias. | |
| | | GIT: Stimulates gastric acid and digestive enzymes secretion. | |
| | | Kidney: Weak diuretic from increased glomerular filtration and reduced tubular sodium | |

| | | reabsorption. | |
|---|-----|--|--|
| | | Lung: Bronchodilation by relaxing airway smooth muscle and inhibits antigen-induced release of histamine from lung tissue. | |
| How do these effect correlate to its serum | 1 2 | Theophylline has a narrow therapeutic window, and its therapeutic and toxic effects are related to its blood level: | |
| | | 5–20 mg/L: Improvement in pulmonary function. Anorexia, nausea, 15-20 mg/L: vomiting, abdominal discomfort, headache, and anxiety occur at concentrations of in some patients: >40 mg/L: Cause seizures or arrhythmias | |
| | | Pass –, CVS & Resp effects, narrow therapeutic window | |
| | | | |
| | | | |

| Thiopentone | Describe the pharmacokinetics of thiopentone | After IV bolus, rapidly crosses the blood-brain barrier. Plasma:brain equilibrium occurs < 1 min because of high lipid solubility. Rapidly diffuses out of the brain and highly vascular tissues, and redistributed to muscle and fat. Metabolized at rate of 12–16% per hour. <1% of the administered dose excreted unchanged by kidney. | |
|------------------|--|---|--|
| | What adverse effects does it cause when used as an anaesthetic induction agent ? | Drops BP, SV, CO due to myocardial depressant effect and increased venous capacitance. Apnoea. Rarely precipitates porphyric crisis by inducing ALA synthase in liver Pass – 2 phase concept, hypotension | |
| Fluoroquinolones | What is the mechanism of action of fluoroquinolones ?What are the mechanisms of resistance to fluoroquinolones ?What are the clinical uses ciprofloxacin ? | DNA gyrase inhibitor/blocks protein production Resistance is due to one or more point mutations in the quinolone binding region of the target enzyme or to a change in the permeability of the organism. UTI Bacterial diarrhoea caused by Shigella, Salmonella, toxigenic <i>E coli</i>, Campylobacter Soft tissue, bone, joint, intra-abdominal and respiratory tract infections Treatment against multidrug-resistant organisms (pseudomonas and enterobacter) Prophylaxis and treatment against anthrax Gonococcal infection Chlamydial urethritis or cervicitis TB and atypical mycobacterial infections Eradication of meningococcal carrier state Prophylaxis in neutropenic patients Pass – DNA gyrase inhibition, 3 organ system uses | |

ACEM PRIMARY 1/2008 Pharmacology VIVA Morning Day 2 Candidate Number...... AGREED MARK......

| TOPIC | QUESTION | ESSENTIAL KNOWLEDGE | NOTES |
|-----------------|---|---|---|
| Bioavailability | Define the term bioavailability | Fraction of unchanged drug reaching the systemic circulation following administration by any route. | Need close approximation of defn |
| | What factors limit drug bioavailability following oral administration ? | (1) Extent of absorption(2) First-pass elimination (liver, gut) | Identify both factors (prompt if necessary) |
| | What methods of drug delivery are used to overcome bioavailability problems ? | Alternative route – sublingual, rectal, transdermal parenteral Administration pro-drug, increased dose | Give one example of an alternative route |
| Nitrates | What is the cellular mechanism of action of GTN ? | Denitration by glutathione S-transferase. Free nitrite ions released and form NO. NO activates guanylyl cyclise leading to increased cGMP and dephosphorylation of myosin and smooth muscle relaxation (precise mechanism unknown) | Production of NO leading to smooth muscle relaxation to pass |
| | How does GTN relieve angina pain ? | Venodilation leads to reduced venous return, reduce ventricular volume and reduced heart wall tension. This reduces myocardial O2 requirement. | Need to know that venodilation and reduced venous is major factor reducing myocardial o2 requirement. |
| | Outline the pharmacokinetics of sublingual GTN | Oral bioavailability is low due to extensive first pass hepatic metabolism by high capacity organic nitrate reductase. Rapid and efficient absorption by sublingual or intranasal routes but rapid elimination (t1/2 2-8 mins) and duration of action (15-30 mins) due to high capacity hepatic metabolism. Denitrited metabolites conjugated to to glucuronide and excreted in urine. | Poor oral bioavailability due extensive first pass metabolism and effective alternative routes of administration to pass |
| Beta Lactams | How does Penicillin exert its action ? | Inteferes in bacterial cell wall synthesis by binding to penicillin-binding-protein and preventing removal of terminal d-alanyl-d-alanine from peptides preventing crosslinking and formation of peptidoglycan. | Inhibits bacterial cell wall synthesis to pass. |

| Antiemetics | What are the mechanisms of resistance to B Lactam antibiotics ? What clarrrrsses of drug can be used as antiemetics ? | (1) Inactivation by B-lactamase (2) Modification of target PBPs (3) Impaired penetration of durg to target PBPs (4) Presence of efflux pumps (1) Serotonin 5-HT3 antagonists: the "trons" (2) Phenothiazines: prochlorperazine, promethazine (3) Butyrophenones: haloperidol (4) Substituted benzamides: metoclopramide (5) H1 antihistamines: diphenhydramine | Inactivation of B-lactamase and one other to pass Name three groups to pass – if name agents, prompt for group or mechanism of action. |
|--|---|--|--|
| | List and explain the adverse effects of prochlorperazine ? | (6) Anticholinergics: hyoscine (Benzos, Cannabinoids, Corticosteroids) Acute dystonia (dopamine blockade) Sedation (antihistamine effects) Anticholinergic effects (antimuscarine effects) Allergy | Acute dystonia + one other to pass |
| Drugs Binding To Biogenic Amine Transporters | How do anti-depressants exert their action ? | Thought to enhance amine-dependent synaptic transmission (serotonin and noradrenalin) by: (1) Inhibition of metabolism within nerve terminal (MAOIs) (2) Inhibition of reuptake from synapse (TCAs, SSRIs) (3) Increased release due to antagonism of specific serotonin and alpha2 noradrenalin receptors (Mirtazapine) | 2/3 mechanisms to pass |
| | What are the relative advantages of different classes of antidepressants ? (Direct to adverse effects if no response) | Adverse effect profile Cost Efficacy Risk of overdose Dosing schedule Drug interactions | Able to discuss pros and cons of at least two |